Comparison of switch to fingolimod and continued treatment with glatiramer acetate or interferon Beta in patients with relapsing multiple sclerosis: Follow-up analysis of the EPOC clinical trial

Abstract

EPOC was an open, randomized, phase IV clinical trial comparing the quality-of-life endpoints concerning patients suffering from relapsing multiple sclerosis who were switched from disease-modifying injectables to fingolimod with those concerning patients who continued the former treatment. This tudy has shown that many parameters assessed by both physicians and patients, including the overall satisfaction with therapy, were better in patients using fingolimod

Keywords

• multiple sclerosis
• fingolimod
• quality of life
• EPOC trial